Reversibly switchable proteins are powerful tools with which to explore protein function in vitro and in vivo. For example, the activity of many proteins fused to the hormone-binding domain of the modified oestrogen receptor (ER TAM ) can be regulated by provision or removal of 4-hydroxytamoxifen (4-OHT). Despite the widespread use of ER TAM fusions in vivo, inadequate data are available as to the most efficacious routes for systemic tamoxifen delivery. In this study, we have used two well-characterized ER TAM fusion proteins, both reversibly activated by 4-OHT, to compare the effectiveness and kinetics of 4-OHT delivery in mice in vivo by either tamoxifen in food or by intraperitoneal injection. Our data indicate that dietary tamoxifen offers an effective, facile and ethically preferable means for long-term activation of ER TAM fusion proteins in vivo.
INTRODUCTION
In classical mouse genetics, the function of a specific gene is irreversibly mutated or deleted in the germ-line and the phenotype that manifests is an amalgam of both, the direct consequences of the mutation together with the extent to which those direct consequences drive compensatory adaptation during development. Such developmental compensation, together with the embryonic lethality associated with other mutations, severely limits the information that such 'germ-line' genetics can provide on the roles played by genes in adult tissues. The inability to reverse the germ-line alterations of genes in classical genetics further limits determination of adult gene function. Such considerations have fostered the idea of using reversibly switchable genetic technologies, whereby wild-type gene functions may be reversibly toggled on and off, at will, in adult mice, either systemically or tissue by tissue.
When fused to a heterologous protein, the modified oestrogen receptor ligand-binding domain (ER TAM ) may be used to render that protein rapidly and reversibly ectopically regulatable by the ER TAM ligand 4-hydroxytamoxifen (4-OHT), see http://www.picard. ch/downloads for annotated list of proteins that have successfully been regulated by fusion with a steroid-binding domain. Most notably, ER TAM fusions with various oncoproteins and tumour suppressor proteins have been successfully employed in transgenic and knock-in mouse cancer models to ascertain the roles of such effectors in both tumour initiation and maintenance. [1] [2] [3] [4] However, the efficiency of tamoxifen delivery and activation of ER TAM fusion proteins has hitherto only been assessed for 'hit-and-run' activation functions, such as activation of Cre-ER TAM by determining the extent of recombination of specific floxed alleles. [8] [9] [10] However, such acute studies offer little guidance as to the practical utility of tamoxifen administration in sustaining the activities of ER TAM fusion proteins over protracted periods in vivo, as is required for modelling chronic pathologies such as cancer that typically requires long-term administration of ER TAM ligand to sustain activities of oncogenic ER TAM fusion proteins. For such purposes, 4-OHT is prohibitively expensive and, consequently, most in vivo studies instead use tamoxifen, which is cheaper and is readily metabolized by the liver into the active 4-OHT metabolite by the cytochrome P450 CYP2D6 and CYP3A4 isoforms. 5 Unfortunately, tamoxifen has a relatively short half-life in vivo (about 16 h) 6 and is poorly soluble in aqueous preparations so, to date, the most consistent results for sustained activation of ER TAM fusion proteins have been obtained through daily intraperitoneal injection (i.p.) of tamoxifen dispersed in vegetable oil. 7 However, administration via this route is both labour-intensive and ethically debatable because it can result in sterile peritonitis due to the accumulation of oil. Indeed, six weeks of daily injections is the maximum that can be realistically tolerated, therefore, extended treatment with tamoxifen is usually impractical. Despite the widespread use of ER TAM fusions in vivo, scant data are available on the most efficacious routes for long-term tamoxifen delivery. We therefore sought to ascertain the kinetics of tamoxifeninduced activation of ER TAM -fusion proteins in response to various routes of tamoxifen administration and to investigate more sustainable tamoxifen delivery methods for long-term analysis.
RESULTS AND DISCUSSION
We employed two well-characterized mouse models whose biologies are dependent upon activities of ER TAM fusion proteins. First, the pIns-MycER TAM mouse, in which transgenic overexpression of the 4-OHT-dependent allele of the c-Myc oncoprotein, MycER TAM , is driven from the rat insulin promoter in pancreatic β-cells. Administration of tamoxifen to such animals activates oncogenic Myc, triggering widespread Myc-induced β-cell apoptosis and islet involution. However, co-expression of the antiapoptotic protein Bcl-x L in β-cells blocks Myc-induced apoptosis, whereupon Myc activation drives and maintains synchronous, rapid, persistent and progressive β-cell expansion accompanied by angiogenesis, inflammation, invasion and tumorigenesis. 11 Subsequent de-activation of MycER TAM triggers complete regression of the β-cell tumours. Second, we used Trp53 tm1Gev mice (hereafter called p53 KI/KI ), in which both copies of endogenous p53 are replaced by a gene encoding the 4-OHT-dependent p53 allele p53ER TAM . 4 In these animals, p53 function is continuously dependent upon the provision of 4-OHT ligand. Hence, in the absence of tamoxifen, p53 KI/KI mice are effectively p53 null and radiosensitive tissues, such as thymus, spleen and intestinal epithelium, exhibit significant refractoriness to radiation-induced apoptosis, as they do in p53 − / − mice. However, p53-dependent radiosensitivity of p53 KI/KI tissues is rapidly restored upon systemic administration of tamoxifen. 4 To assess whether dietary tamoxifen is a feasible means for regulating ER TAM protein activity in vivo, we first assessed the dynamics of oncogenic MycER TAM activation in pIns-MycER TAM ; RIP7-Bcl-x L mice (also known as Tg(Ins-BCL2L1)2Ksp;Tg(Ins-MYC/Er) 1Gev mice). 11 Myc-driven pancreatic insulinomas were induced in 8-to 15-week-old pIns-MycER TAM ;RIP7-Bcl-x L (n ⩾ 3) mice by either daily i.p. of 0.8 mg tamoxifen in oil or dietary tamoxifen for 7 days. β-cell proliferation in pancreata was then assessed by immunohistochemical staining for the proliferative marker Ki67. Control RIP7-Bcl-x L mice exhibited little β-cell proliferation ( o0.4 Ki67 positive cells per unit area) irrespective of tamoxifen delivery or route of administration. By contrast, administration of tamoxifen to pIns-MycER TAM ;RIP7-Bcl-x L mice, by either injection or diet, elicited similarly dramatic levels of β-cell proliferation (P = 0.85, Figure 1 ), indicating that MycER TAM -activating doses of tamoxifen are achievable by both administration methods. Hence, administration of tamoxifen through diet is an effective means for achieving ER TAM -activating levels of 4-OHT in tissues in vivo.
To establish the kinetics and persistence of tamoxifendependent activation of ER TAM proteins in tissues in vivo, we used the p53 KI/KI mouse model, assessing 4-OHT-dependent p53 functionality using responses of radiosensitive tissues to pathological doses of γ-irradiation. Tamoxifen was administered to 8-12-week-old homozygous p53 KI/KI mice (and to p53 +/+ and p53 − / − controls) by either (i) single intraperitoneal bolus of 1 mg tamoxifen dissolved in oil or by feeding mice with tamoxifenimpregnated food for (ii) 24 h or (iii) 7 days. Mice were then exposed to 2.5 Gy whole body γ-irradiation (Cs source) at various times after bolus tamoxifen administration or after removal from tamoxifenized food, and the thymus and spleen were collected 4 h later. p53 functionality was assessed by quantifying apoptosis in the thymus (immunohistochemical staining for cleaved caspase-3) (Figures 2a-c) and by assaying levels of p21 cip1 expression in the spleen ( Supplementary Figure 1) .
As expected, untreated p53 +/+ control mice exhibited high levels of both apoptosis and p21 cip1 expression following irradiation whereas non-tamoxifen-treated p53 KI/KI mice (as well as p53 − / − controls), exhibited little ( Supplementary Figure 2) . Significant apoptosis and p21 cip1 expression were evident in the radiosensitive tissues of p53 KI/KI within only 2 h of i.p. administration of 1 mg tamoxifen, peaking around 4 h post injection and then falling back to background levels between 24-48 h post treatment. Hence, tamoxifen adminstered i.p. rapidly and systemically restores functionality to p53ER TAM tissues in vivo. Attenuation of radiosensitivity was more rapid (50% reduction in p21 cip1 expression by 8 h post irradiation) in mice given a single i.p. injection of a reduced (0.8 mg) tamoxifen dose (estimated to be equivalent to the dose received via chow, see below) whereas a higher dose (4 mg) elicited a more sustained p53ER TAM functionality (more than 80% of peak p21 cip1 expression was maintained to 8 h post irradiation). However, higher doses of tamoxifen did not increase the extent of p21 cip1 activation at 2 h post irradiation (Supplementary Figure 3A) , indicating that the level of p53 activation is directly dependent on tamoxifen availability and that tamoxifen doses via i.p. greater than 0.8 mg tamoxifen are fully saturating for p53ER TAM in vivo and that higher doses merely confer more prolonged ER TAM fusion protein activity.
We next investigated the kinetics of ER TAM activation when delivering tamoxifen through food. p53 KI/KI mice exposed to tamoxifen-containing food for 24 h exhibited no measurable increase in radiosensitivity. This is most likely due to the fact that over the first 24-h period, mice only ate on average 2.3 g of tamoxifen-containing food (n = 14, range 1-3 g), which is around half of their normal daily intake and, consequently, exhibited on average 8.5% weight loss (n = 14, range 0-19%). We guess that the level of tamoxifen in the animals is insufficient to activate p53ER TAM and, for this reason, dietary tamoxifen is unsuitable for studies requiring acute activation of ER TAM proteins. However, tissues of p53 KI/KI mice exposed to tamoxifen-containing food for 7 days was sufficient to render tissues fully radiosensitive, as evidenced by extensive radiation-induced apoptosis and p21 cip1 expression that then fell to background levels by 16-24 h of surcease of dietary tamoxifen (Figure 2 and Supplementary Figure 1C ). The actual DNA damage induced by γ-irradiation, as assessed by phospho-Histone H2A.X staining, was comparable in all tissues irrespective of tamoxifen provision (Supplementary Figure 3B) .
To examine directly the rate of metabolism/excretion of tamoxifen in each experimental system, we determined the level of 4-OHT, the ER TAM -activating tamoxifen metabolite, in the blood plasma of pure C57BL6J mice ( Supplementary Figure 4) using LC/MS (liquid chromatography-mass spectrometry). These studies confirmed that plasma 4-OHT is evident 2 h post single i.p. administration of 0.8 mg tamoxifen, returning to background levels after 24-48 h. Sustained dietary administration of tamoxifen-containing food for 7 days resulted in significant plasma 4-OHT and this fell to undetectable levels between 8 and 24 h after surcease of dietary tamoxifen. Thus 4-OHT, once tamoxifen has been ingested or injected, is cleared from tissues within 24 h, attesting to the need for repeated daily administration of tamoxifen in situations to maintain ER TAM fusion protein function. Once animals have become acclimatized to dietary tamoxifen for at least 7 days they receive on average a 0.8 mg daily dose of tamoxifen over a 24-h period from grazing on food. This is reflected in the observation that 4-OHT levels and corresponding functional readout of ER TAM protein activity is lower than seen via a single 1 mg i.p. injection and decays to background levels rather more rapidly. Nonetheless, we guess that tamoxifen delivery via the food maintains more consistent ER fusion activity than can periodic i.p. delivery. Of note, in this study we used either a mixed 129-C57BL6/J or pure C57BL6/J mouse strains-although we have not observed any strain-dependent differences in tamoxifen availability, this remains a possibility that should be considered in further in vivo studies using switchable ER fusion proteins.
To investigate the possibility of any adverse impact on general health through long-term administration of tamoxifen in food, mice were placed on a tamoxifenized diet for 18 weeks. Over the first week, mice lost an average of 16% body weight, apparently due to aphagia, but then recovered normal body weight and thereafter remained healthy, with no abnormalities detectable in any tissues (Figure 2d ). Given the hazards associated with repeated i.p. injection, our data confirm the administration of tamoxifen in food as an effective and ethically preferable means of maintaining ER TAM activity for prolonged periods in vivo. Immunohistochemistry was performed on paraffin-embedded 4 μm sections which were deparaffinised, treated with citrate buffer for epitope retrieval and endogenous peroxidises blocked in 3% H 2 O 2 . Staining was performed using the Rabbit VECTASTAIN ELITE ABC horseradish peroxidase kit (Vector Laboratories, Burlingame, CA, USA) following the manufacturer's protocol. Primary antibody: anti-caspase-3 antibody (Cell Signalling Technology, Danvers, MA, USA; clone: 5A1E 1:50). Quantification was carried out by counting positive stained cells per field of vision, and two representative fields per mouse per time point were chosen for counting (n ⩾ 3 mice). For i.p. injections, tamoxifen base (T5648, Sigma-Aldrich, St Louis, MO, USA) was dissolved at 100 mg/ml in 100% ethanol by heating to 55°C for 10 min, diluted in autoclaved sunflower oil to give a final concentration of 10 mg/ml and stored at − 20°C until use. Before i.p. injection, tamoxifen in oil was warmed to 55°C for 10 min. Dietary tamoxifen was delivered in Tam400/CreER tamoxifen pellets (400 mg tamoxifen citrate per kg supplemented standard diet Global 2016 pellets), supplied by Harlan Teklad Europe, Boxmeer, The Netherlands. All procedures with animals were carried out in accordance with Home Office UK guidelines.
